Home Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...
 

Keywords :   


Gilead Announces Phase 3 Results for an All-Oral, Sofosbuvir-Based...

2013-11-02 15:57:50| Biotech - Topix.net

Gilead Sciences, Inc. today announced results from a Phase 3 study, PHOTON-1, evaluating the investigational once-daily nucleotide analogue sofosbuvir for the treatment of chronic hepatitis C virus infection among patients co-infected with HIV.

Tags: results phase announces gilead

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
28.11 HEXAGON TR SET UP
28.1121dc hg
28.111EX D
28.11 Bucchus IMP24 FMH-RSM/M
28.11
28.11specialites TA carmina 46-36
28.11HUNTER×HUNTER
28.11
More »